EscharEx is an enzyme commercialized by MediWound, with a leading Phase II program in Diabetic Foot Ulcers;Venous Leg Ulcers (Crural Ulcer). According to Globaldata, it is involved in 4 clinical trials, of which 3 were completed, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of EscharEx’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for EscharEx is expected to reach an annual total of $6 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
EscharEx Overview
EscharEx is under development for the debridement of chronic and other hard to heal venous leg ulcers, diabetic foot ulcers (lower extremity), traumatic/post operative wounds. It is applied topically. The drug candidate is a proteolytic enzyme. The development of the drug candidate is based on proteolytic enzymatic technology.
MediWound Overview
MediWound is a biopharmaceutical company that develops, manufactures and markets novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hard-to-heal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns (deep partial and full-thickness thermal burns). EscharEX, pipeline drug candidate for the removal of damaged, dead or infected tissues from chronic wounds; MWPC003, a pre-clinical candidate for treating connective tissue Disorders. The company markets NexoBrid in Europe and Israel through its own commercial organization and in Russia, Peru, India, Bangladesh, South Korea, Argentina through distributors. MediWound is headquartered in Yavne, Israel.
The company reported revenues of (US Dollars) US$18.7 million for the fiscal year ended December 2023 (FY2023), a decrease of 29.5% over FY2022. The operating loss of the company was US$15.3 million in FY2023, compared to an operating loss of US$8.4 million in FY2022. The net loss of the company was US$6.7 million in FY2023, compared to a net loss of US$19.6 million in FY2022.
For a complete picture of EscharEx’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.